BioDelivery Sciences International Inc
F:BD5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lasertec Corp
TSE:6920
|
JP |
BioDelivery Sciences International Inc
Total Current Assets
BioDelivery Sciences International Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
Total Current Assets
$202.1m
|
CAGR 3-Years
45%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Assets
$55.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Assets
$29.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Assets
$42.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Assets
$43.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Assets
$55.6B
|
CAGR 3-Years
46%
|
CAGR 5-Years
26%
|
CAGR 10-Years
16%
|
|
BioDelivery Sciences International Inc
Glance View
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
See Also
What is BioDelivery Sciences International Inc's Total Current Assets?
Total Current Assets
202.1m
USD
Based on the financial report for Dec 31, 2021, BioDelivery Sciences International Inc's Total Current Assets amounts to 202.1m USD.
What is BioDelivery Sciences International Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
37%
Over the last year, the Total Current Assets growth was 11%. The average annual Total Current Assets growth rates for BioDelivery Sciences International Inc have been 45% over the past three years , 37% over the past five years .
